Customer Publication

Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy

Authors: R. Narayanaswamy et al.

Journal: Pharmaceutical Research (2021)

Institution: Northeastern University

Research Areas: Drug activity

Cell Lines: MDA-MD-231 (Human mammary carcinoma cell line)

Summary: Improving the various properties, such as biodistribution and solubility, are the main driving force for using nano-carries in drug deliveries. In this study, the authors have used monoclonal antibody modified immunoliposomes for targeted delivery of paclitaxel and salinomycin for cancer therapy. Researchers have shown that a combination of drugs increases therapeutical efficacy when delivered in immunoliposomes. HoloMonitor M4 was used to study cell killing, cell division and proliferation post-treatment.

Keywords: HoloMonitor M4, cell Proliferation and cell Morphology, cancer therapy

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
+46 46 38 60 80

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
+1 617-963-5150


VAT: SE556542781101

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2